Antiviral therapy, HBsAg seroclearance and late recurrence of hepatitis B-related hepatocellular carcinoma
- PMID: 35863489
- DOI: 10.1016/j.jhep.2022.07.005
Antiviral therapy, HBsAg seroclearance and late recurrence of hepatitis B-related hepatocellular carcinoma
Keywords: Antiviral therapy; Hepatocellular carcinoma; Recurrence; Seroclearance.
Conflict of interest statement
Conflict of interest All authors declared no conflict of interest. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment in
-
Reply to: Correspondence on "Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection".J Hepatol. 2022 Nov;77(5):1472-1474. doi: 10.1016/j.jhep.2022.07.032. Epub 2022 Aug 18. J Hepatol. 2022. PMID: 35987276 No abstract available.
Comment on
-
Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection.J Hepatol. 2022 Oct;77(4):939-946. doi: 10.1016/j.jhep.2022.05.014. Epub 2022 May 26. J Hepatol. 2022. PMID: 35643206
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
